Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.


Tositumomab and Iodine I 131 Tositumomab Product Approval Information - Licensing Action 6/27/03

Proper name: Tositumomab and Iodine I 131 Tositumomab 
Tradename: Bexxar
Manufacturer: Corixa Corporation, Seattle, WA, License #1614
Indication for Use: Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy
Approval Date: 6/27/2003
Type of submission: Biologics license application


Labeling (PDF)

Page Last Updated: 09/30/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English